Safety and Efficacy of Anricfen for Postoperative Analgesia and Rehabilitation Promotion After Pancreaticoduodenectomy.Intervention Measures: For Normal Adults, Administer Ariceptin Injection Intravenously Post-operation at a Dose of 1 μg/Kgevery 8 Hours for Three Consecutive Days After Surgery.
The Safety and Efficacy of Aniracetamfen for Postoperative Analgesia and Rehabilitation After Pancreaticoduodenectomy: A Single-center, Single-arm Clinical Study
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
35 participants
Nov 25, 2025
INTERVENTIONAL
Conditions
Summary
Exploring the effectiveness and safety of early use of Ariceptinfen after pancreaticoduodenectomy in alleviating postoperative pain and promoting recovery of patients. Main objective: To explore the analgesic effect of Anricfen after pancreaticoduodenectomy. Secondary objective: To explore the impact of Anricfen on the accelerated recovery after pancreaticoduodenectomy. Exploratory objective: To investigate the biomarkers of Anricfen's analgesic effect after pancreaticoduodenectomy, as well as its correlation factors with tumor pathology.
Eligibility
Inclusion Criteria4
- Patients who underwent pancreatic surgery, including pancreaticoduodenectomy (PD), pancreatic-preserving pancreaticoduodenectomy (PPPD), and laparoscopic pancreaticoduodenectomy (LPD)
- Age ≥ 18 years old and < 80 years old
- ASA Ⅰ-Ⅲ
- Be able to clearly understand and voluntarily participate in the research
Exclusion Criteria8
- Merging severe primary diseases involving the heart, brain, liver, kidneys and hematopoietic system
- History of long-term use of psychotropic drugs and cognitive dysfunction
- Having a history of acute poisoning from alcohol, sleeping pills, painkillers or other drugs that affect the central nervous system
- Pregnancy or lactation period
- History of allergy to NSAIDs, opioids, or to the test medication
- Drug users, alcoholics, and opiate abusers
- Those who had a history of chronic pain before the operation and a history of long-term use of analgesics and/or sedatives
- Those who had thyroid dysfunction before the operation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Postoperatively, administer Anrikefon injection intravenously at a dose of 1 μg/kg every 8 hours for three consecutive days.
Postoperatively, intravenous injection of Anrikefon injection was administered at a dose of 1 μg/kg, every 8 hours, for three consecutive days as an intervention
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07514637